AI is accelerating drug discovery, but investment has concentrated in molecule design—the stage with the best data and clearest tools. The industry’s real constraint lies elsewhere: identifying and validating the right disease mechanism.
AI drug discovery: Focusing on what matters most
calendar_today
September 27, 2026
domain
mckinsey-and-company